Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.65 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.61 |
| ▸ | TNKS | O95271 | 1/20 | 0.61 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.61 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.61 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.61 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.61 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289656 | 0.82 | KMT2A (0.57) | PARP1L3MBTL1CES2CES1MEN1 | |
| SCHEMBL132082 | 0.82 | AKR1C3 (0.63) | KMT2AAKR1C3 | |
| SCHEMBL27840823 | 0.79 | AKR1C3 (0.65) | TSHRKMT2AAKR1C3 | |
| SCHEMBL29503138 | 0.78 | PARP1 (1.00) | PARP1PARP10TNKSPARP15PARP14 | |
| SCHEMBL283787 | 0.78 | PARP1 (1.00) | PARP1PARP10TNKSPARP15PARP14 | |
| SCHEMBL28870970 | 0.78 | MEN1 (0.73) | PARP1PARP10TNKSPARP15PARP14 | |
| SCHEMBL177641 | 0.78 | SMN1; SMN2 (0.55) | PARP1TSHRPOLBMAPTBLM | |
| Hydrochloric Acid SCHEMBL407554 | 0.77 | PARP1 (0.96) | PARP1PARP10TNKSPARP15PARP14 | |
| SCHEMBL2531295 | 0.77 | PARP10 (0.83) | PARP1PARP10TNKSPARP15PARP14 | |
| SCHEMBL30434552 | 0.77 | PARP10 (0.83) | PARP1PARP10TNKSPARP15PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023177351-A1 | NF ҚB INDUCING KINASE INHIBITORS AND METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-09-21 | — | — | WO | disclosed |
| US-11440887-B2 | Substituted 1,2,3,4-tetrahydroquinolines as inhibitors of repair enzyme 8-oxoguanine deoxyribonucleic acid glycosylase activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-09-13 | — | — | US | disclosed |
| US-20200190034-A1 | Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3664790-A1 | INHIBITORS OF BASE EXCISION REPAIR ACTIVITY AND THERAPEUTIC METHODS BASED THEREON | The Board of Trustees of the Leland Stanford Junior University (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10426766-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| WO-2019032563-A1 | INHIBITORS OF BASE EXCISION REPAIR ACTIVITY AND THERAPEUTIC METHODS BASED THEREON | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-02-14 | — | — | WO | disclosed |
| EP-3037420-B1 | PROCESS FOR PREPARING AN INTERMEDIATE TO MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20180200246-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-9949963-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007130780-A2 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| US-20050059726-A1 | Pyrrolidine-2-ones as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-17 | — | — | US | disclosed |
| EP-1456172-A1 | PYRROLIDINE-2-ONES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-09-15 | — | — | EP | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003053925-A1 | PYRROLIDINE-2-ONES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | PARP1 4767/4885PARP10 4070/4885TNKS 3473/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | PARP1 4385/4885PARP10 3629/4885TNKS 2352/4885 |
| US-20180200246-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | OPRM1, SIGMAR1, OPRD1 | PARP1 4447/4885PARP10 3475/4885TNKS 4547/4885 |
| US-10426766-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | OPRM1, SIGMAR1, OPRD1 | PARP1 4447/4885PARP10 3475/4885TNKS 4547/4885 |
| US-11440887-B2 | Substituted 1,2,3,4-tetrahydroquinolines as inhibitors of repair enzyme 8-oxoguanine deoxyribonucleic acid glycosylase activity | OGG1, UNG, MPG | PARP1 69/4885PARP10 155/4885TNKS 269/4885 |
| US-20050059726-A1 | Pyrrolidine-2-ones as factor xa inhibitors | TFPI, F2, SERPINC1 | PARP1 180/4885PARP10 202/4885TNKS 217/4885 |
| US-20200190034-A1 | Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon | OGG1, UNG, MPG | PARP1 67/4885PARP10 79/4885TNKS 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.